InSite Vision Announces Webcast of Presentation at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

InSite Vision Incorporated (AMEX:ISV) today announced that S. Kumar Chandrasekaran, Ph.D., Chairman, CEO and President, will present an overview of the company at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, Tuesday, November 6, 2007 at 9:50 a.m. Eastern Standard Time in New York. The presentation will be webcast and may be accessed live on the investor relations section of the company’s website at www.insitevision.com. The presentation will be available on this link for a limited time following the conference. About InSite Vision InSite Vision develops novel ophthalmic and topical anti-infective products. The company’s lead product, AzaSite (azithromycin ophthalmic solution) 1% for the topical treatment of bacterial conjunctivitis (pink eye), was launched in August 2007 in the United States by Inspire Pharmaceuticals, its commercial partner in the United States and Canada. Based on its proprietary azithromycin-DuraSite® topical anti-infective technology platform, InSite is expanding its portfolio of ophthalmic products by developing AzaSite Plus™ and AzaSite Xtra™, whose product features have the potential to provide significant advantages not available with current treatment options. In addition, InSite is evaluating the use of its azithromycin-DuraSite platform to develop topical anti-infective products outside of the market category of ophthalmology, including the development of AzaSite Otic for ear infections.